Zhijie Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zhijie Lu has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
Kai Wei
Shanghai Eastern Hepatobiliary Surgery Hospital
7 shared publicationsJiao Zhu
Department of Anesthesiology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China
6 shared publications- Kun-Ming Tao
Department of Anesthesiology, Eastern Hepatobiliary Surgery Hospital, Shanghai, China
5 shared publications Qianbo Chen
Department of Anesthesiology and Intensive Care, Third Affiliated Hospital of Second Military Medical University, Shanghai, China
4 shared publicationsCheng-Cheng Zhu
Shanghai Eastern Hepatobiliary Surg Hosp, Dept Anesthesiol, 225 Changhai Rd, Shanghai 200438, Peoples R China
3 shared publicationsHai-Bo Qiu
Shanghai Eastern Hepatobiliary Surg Hosp, Dept Anesthesiol, 225 Changhai Rd, Shanghai 200438, Peoples R China
3 shared publications
Latest Publications
- 17 February 2026
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (7) , 2989-3005
S1P2 Reduces Mast Cell Activation and Colonic Inflammation of L-Arginine-Induced Acute Pancreatitis
Acute pancreatitis (AP) is a serious pancreatic disorder and colonic inflammation is involved in the progression of AP. However, the role of mast cells in the regulation of colonic inflammation in AP has been less studied; thus, we explored the role of mast cells in the regulation of colonic inflammation. An AP model was established by intraperitoneal injection of L-arginine or caerulein. Colonic inflammation in AP was tested using H&E staining. The mRNA levels were quantified using qRT-PCR. The protein level of sphingosine-1-phosphate receptor 2 (S1P2) was quantified using western blotting or immunohistochemistry. The gut microbiota was analyzed using 16S rRNA sequencing. The Western blot analysis revealed that S1P2 expression was decreased by 0.63-fold in L-arginine-AP-induced colonic inflammation. Ketotifen, a second-generation H1-antihistamine and mast cell stabilizer, increased the survival rate (90%) in the L-arginine-AP model and increased the mRNA level of S1P2 by 1.33-fold and protein expression by 1.47-fold, suggesting that ketotifen inhibited mast cell activation through the S1P2 pathway. Similarly, treatment with the S1P2 agonist CYM-5520 in the L-arginine-AP model did not result in death and decreased the proportion of mast cells in the spleen by 1.58-fold. Moreover, gut microbiome analysis revealed that the abundance of proteobacteria decreased in L-arginine-AP mice pretreated with CYM-5520. In vitro experiments revealed a 2.1-fold decrease in S1P2 expression following mast cell stimulation, and the absence of S1P2 promoted mast cell degranulation. This study provides evidence that S1P2 can ameliorate colonic inflammation in an L-arginine-induced AP mouse model by inhibiting mast cell activation.
- 17 February 2026
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (7) , 2989-3005
S1P2 Reduces Mast Cell Activation and Colonic Inflammation of L-Arginine-Induced Acute Pancreatitis
Acute pancreatitis (AP) is a serious pancreatic disorder and colonic inflammation is involved in the progression of AP. However, the role of mast cells in the regulation of colonic inflammation in AP has been less studied; thus, we explored the role of mast cells in the regulation of colonic inflammation. An AP model was established by intraperitoneal injection of L-arginine or caerulein. Colonic inflammation in AP was tested using H&E staining. The mRNA levels were quantified using qRT-PCR. The protein level of sphingosine-1-phosphate receptor 2 (S1P2) was quantified using western blotting or immunohistochemistry. The gut microbiota was analyzed using 16S rRNA sequencing. The Western blot analysis revealed that S1P2 expression was decreased by 0.63-fold in L-arginine-AP-induced colonic inflammation. Ketotifen, a second-generation H1-antihistamine and mast cell stabilizer, increased the survival rate (90%) in the L-arginine-AP model and increased the mRNA level of S1P2 by 1.33-fold and protein expression by 1.47-fold, suggesting that ketotifen inhibited mast cell activation through the S1P2 pathway. Similarly, treatment with the S1P2 agonist CYM-5520 in the L-arginine-AP model did not result in death and decreased the proportion of mast cells in the spleen by 1.58-fold. Moreover, gut microbiome analysis revealed that the abundance of proteobacteria decreased in L-arginine-AP mice pretreated with CYM-5520. In vitro experiments revealed a 2.1-fold decrease in S1P2 expression following mast cell stimulation, and the absence of S1P2 promoted mast cell degranulation. This study provides evidence that S1P2 can ameliorate colonic inflammation in an L-arginine-induced AP mouse model by inhibiting mast cell activation.
- Open Access
- 17 February 2026
- Published by Elsevier in Brain Research Bulletin
- Vol. 237, 111784
Neural circuitry remodeling in chronic pain and depression comorbidity: Toward an emotion-perception integration network model
- 17 February 2026
- Published by Elsevier in Brain Research Bulletin
- Vol. 237, 111784
Open AccessNeural circuitry remodeling in chronic pain and depression comorbidity: Toward an emotion-perception integration network model
- Open Access
- 30 January 2026
- Published by Wolters Kluwer Health in Pain
- Vol. 167 (4) , 962-975
Mast cell corticotropin-releasing factor receptor 1 contributes to pancreatic cancer pain via mitogen-activated protein kinase/sphingosine kinases type 1 signaling
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer often accompanied by persistent abdominal pain and stress, significantly compromising patients' quality of life. Previous studies have identified mast cells as crucial contributors to pancreatic cancer–related pain. This study aimed to investigate the role of the mast cell receptor corticotropin-releasing factor receptor 1 (CRFR1) and delineate its underlying mechanisms in mediating pancreatic pain. In the current study, we demonstrated that painful patients with PDAC exhibited markedly increased mast cell infiltration in peritumoral tissues, but not in tumor tissues, along with elevated levels of CRF and mast cell–specific CRFR1 expression, compared to asymptomatic patients. Consistently, in orthotopic PDAC mice models, flow cytometry and immunofluorescence staining confirmed increased CRFR1 expression in mast cells. Both pharmacological inhibition of CRFR1 and mast cell–specific CRFR1 knockout suppressed mast cell degranulation and alleviated cancer pain in male and female mice. Mechanistically, RNA sequencing, western blotting, and enzyme-linked immunosorbent assay indicated that CRFR1 activated mitogen-activated protein kinase (MAPK) pathway signaling, upregulated sphingosine kinases type 1 (SPHK1) expression, and increased sphingosine-1-phosphate (S1P) levels. A rescue experiment revealed that MAPK inhibition blocked CRFR1-induced SPHK1 upregulation in vitro. Importantly, the SPHK1 inhibitor PF543 reduced abdominal hyperalgesia in mice, whereas this effect was abolished in mast cell deficient mice. Moreover, SPHK1 knockdown by siRNA abolished CRFR1-induced mast cell degranulation. These findings highlight the critical role of mast cell CRFR1 in mediating abdominal hyperalgesia and identify the MAPK/SPHK1/S1P axis as an essential pathway, suggesting that targeting mast cell CRFR1 may be a promising therapeutic strategy for managing pancreatic cancer pain.
- 30 January 2026
- Published by Wolters Kluwer Health in Pain
- Vol. 167 (4) , 962-975
Open AccessMast cell corticotropin-releasing factor receptor 1 contributes to pancreatic cancer pain via mitogen-activated protein kinase/sphingosine kinases type 1 signaling
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer often accompanied by persistent abdominal pain and stress, significantly compromising patients' quality of life. Previous studies have identified mast cells as crucial contributors to pancreatic cancer–related pain. This study aimed to investigate the role of the mast cell receptor corticotropin-releasing factor receptor 1 (CRFR1) and delineate its underlying mechanisms in mediating pancreatic pain. In the current study, we demonstrated that painful patients with PDAC exhibited markedly increased mast cell infiltration in peritumoral tissues, but not in tumor tissues, along with elevated levels of CRF and mast cell–specific CRFR1 expression, compared to asymptomatic patients. Consistently, in orthotopic PDAC mice models, flow cytometry and immunofluorescence staining confirmed increased CRFR1 expression in mast cells. Both pharmacological inhibition of CRFR1 and mast cell–specific CRFR1 knockout suppressed mast cell degranulation and alleviated cancer pain in male and female mice. Mechanistically, RNA sequencing, western blotting, and enzyme-linked immunosorbent assay indicated that CRFR1 activated mitogen-activated protein kinase (MAPK) pathway signaling, upregulated sphingosine kinases type 1 (SPHK1) expression, and increased sphingosine-1-phosphate (S1P) levels. A rescue experiment revealed that MAPK inhibition blocked CRFR1-induced SPHK1 upregulation in vitro. Importantly, the SPHK1 inhibitor PF543 reduced abdominal hyperalgesia in mice, whereas this effect was abolished in mast cell deficient mice. Moreover, SPHK1 knockdown by siRNA abolished CRFR1-induced mast cell degranulation. These findings highlight the critical role of mast cell CRFR1 in mediating abdominal hyperalgesia and identify the MAPK/SPHK1/S1P axis as an essential pathway, suggesting that targeting mast cell CRFR1 may be a promising therapeutic strategy for managing pancreatic cancer pain.
- Open Access
- 14 November 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1708145
Lactate and lactylation in sepsis-associated acute kidney injury: clinical evidence from the MIMIC-IV database and mechanistic insights
Background: Sepsis-associated acute kidney injury (SA-AKI) is a common and severe complication of sepsis, yet early predictors remain limited. Lactate, beyond being a marker of tissue hypoperfusion, may act as a signaling molecule through protein lactylation. This study aimed to investigate the association between lactate levels and SA-AKI risk using the MIMIC-IV database and to explore the potential mechanistic role of lactylation in septic mice. Methods: Adult sepsis patients were identified from the MIMIC-IV (v3.1) database. Patients were stratified by lactate tertiles within 24 h of ICU admission, and lactate clearance (LC) was assessed as a dynamic indicator. The primary outcome was SA-AKI, and secondary outcomes included CRRT use and 28-day mortality. Kaplan–Meier analysis, Cox regression, and restricted cubic spline (RCS) models were performed. In parallel, a murine cecal ligation and puncture (CLP) model was used to evaluate tissue-specific protein lactylation by Western blot, along with serum lactate and hematological parameters. Results: A total of 11,431 patients were included. Higher lactate levels were associated with increased disease severity, higher incidence and severity of SA-AKI, greater use of CRRT, and elevated 28-day ICU and in-hospital mortality. In Cox regression, lactate as both a continuous and categorical variable was independently associated with SA-AKI risk. RCS analysis revealed nonlinear dose–response relationships, with sharply increased risk of SA-AKI above 5.7 mmol/L. In sensitivity analyses ( n = 6,593), higher LC was associated with lower risks of SA-AKI, CRRT use, and mortality. Cox regression confirmed LC as an independent protective factor, while RCS suggested a downward but non-significant trend. In the CLP mouse model, protein lactylation was markedly elevated in the kidney but not in the heart, liver, or spleen, accompanied by higher serum lactate. Conclusion: Elevated lactate levels are independently associated with increased risk of SA-AKI in sepsis patients, whereas higher lactate clearance is linked to improved renal outcomes. Moreover, kidney-specific upregulation of protein lactylation in septic mice suggests a possible molecular link between lactate metabolism and renal vulnerability. These findings highlight lactate and lactylation as both prognostic markers and potential mechanistic contributors in SA-AKI.
- 14 November 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1708145
Open AccessLactate and lactylation in sepsis-associated acute kidney injury: clinical evidence from the MIMIC-IV database and mechanistic insights
Background: Sepsis-associated acute kidney injury (SA-AKI) is a common and severe complication of sepsis, yet early predictors remain limited. Lactate, beyond being a marker of tissue hypoperfusion, may act as a signaling molecule through protein lactylation. This study aimed to investigate the association between lactate levels and SA-AKI risk using the MIMIC-IV database and to explore the potential mechanistic role of lactylation in septic mice. Methods: Adult sepsis patients were identified from the MIMIC-IV (v3.1) database. Patients were stratified by lactate tertiles within 24 h of ICU admission, and lactate clearance (LC) was assessed as a dynamic indicator. The primary outcome was SA-AKI, and secondary outcomes included CRRT use and 28-day mortality. Kaplan–Meier analysis, Cox regression, and restricted cubic spline (RCS) models were performed. In parallel, a murine cecal ligation and puncture (CLP) model was used to evaluate tissue-specific protein lactylation by Western blot, along with serum lactate and hematological parameters. Results: A total of 11,431 patients were included. Higher lactate levels were associated with increased disease severity, higher incidence and severity of SA-AKI, greater use of CRRT, and elevated 28-day ICU and in-hospital mortality. In Cox regression, lactate as both a continuous and categorical variable was independently associated with SA-AKI risk. RCS analysis revealed nonlinear dose–response relationships, with sharply increased risk of SA-AKI above 5.7 mmol/L. In sensitivity analyses ( n = 6,593), higher LC was associated with lower risks of SA-AKI, CRRT use, and mortality. Cox regression confirmed LC as an independent protective factor, while RCS suggested a downward but non-significant trend. In the CLP mouse model, protein lactylation was markedly elevated in the kidney but not in the heart, liver, or spleen, accompanied by higher serum lactate. Conclusion: Elevated lactate levels are independently associated with increased risk of SA-AKI in sepsis patients, whereas higher lactate clearance is linked to improved renal outcomes. Moreover, kidney-specific upregulation of protein lactylation in septic mice suggests a possible molecular link between lactate metabolism and renal vulnerability. These findings highlight lactate and lactylation as both prognostic markers and potential mechanistic contributors in SA-AKI.
- Open Access
- 16 September 2025
- Published by Springer Nature in Research Square
CHRNA5 drives pancreatic cancer progression by promoting tumorigenesis and remodeling immune invasion microenvironment via CAMKII/AKT/NF-κB-CCL20 axis
BackgroundPancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with poor prognosis, characterized by a distinct tumor microenvironment featuring perineural invasion (PNI), high tumor malignancy, and immune evasion. This study aims to identify the crucial cholinergic receptor involved in PDAC progression and elucidate its underlying mechanisms.MethodsTranscriptomic analyses of public PDAC datasets, immunohistochemical staining, and cellular assays were conducted to investigate the enrichment of cholinergic signaling and the tumor-promoting effects of acetylcholine (ACh) in PDAC. We integrated three machine learning models, single-cell RNA-seq reanalysis, in vitro and in vivo experiments to identify alpha5-nicotinic acetylcholine receptor (CHRNA5) as a central mediator of PDAC progression. RNA sequencing and rescue experiments were carried out to elucidate the mechanisms of CHRNA5. Furthermore, KN93, a CaMKII inhibitor, was used to assess the therapeutic potential of targeting CHRNA5-mediated pathways in the PDAC tumor microenvironment.ResultsIntegrated multi-omics analysis, cellular and experimental assays demonstrated the tumor-promoting roles of ACh and CHRNA5, while rescue experiments confirmed that CHRNA5 knockdown abrogated ACh-induced effects. Notably, CHRNA5 inhibition produced more pronounced anti-tumor responses in C57BL/6 mice compared to BALB/c mice. Mechanistically, CHRNA5 shaped an immunosuppressive tumor microenvironment by transcriptionally upregulating CCL20 via CAMKII/AKT/NF-κB signaling, thereby promoting the recruitment of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs). Furthermore, the CAMKII inhibitor KN93 effectively suppressed both tumorigenesis and immune evasion.ConclusionCollectively, our findings identify CHRNA5 as a critical driver of PDAC progression by promoting malignant behaviors and reshaping the immune microenvironment, highlighting its potential as a promising therapeutic target in pancreatic cancer.
- 16 September 2025
- Published by Springer Nature in Research Square
Open AccessCHRNA5 drives pancreatic cancer progression by promoting tumorigenesis and remodeling immune invasion microenvironment via CAMKII/AKT/NF-κB-CCL20 axis
BackgroundPancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with poor prognosis, characterized by a distinct tumor microenvironment featuring perineural invasion (PNI), high tumor malignancy, and immune evasion. This study aims to identify the crucial cholinergic receptor involved in PDAC progression and elucidate its underlying mechanisms.MethodsTranscriptomic analyses of public PDAC datasets, immunohistochemical staining, and cellular assays were conducted to investigate the enrichment of cholinergic signaling and the tumor-promoting effects of acetylcholine (ACh) in PDAC. We integrated three machine learning models, single-cell RNA-seq reanalysis, in vitro and in vivo experiments to identify alpha5-nicotinic acetylcholine receptor (CHRNA5) as a central mediator of PDAC progression. RNA sequencing and rescue experiments were carried out to elucidate the mechanisms of CHRNA5. Furthermore, KN93, a CaMKII inhibitor, was used to assess the therapeutic potential of targeting CHRNA5-mediated pathways in the PDAC tumor microenvironment.ResultsIntegrated multi-omics analysis, cellular and experimental assays demonstrated the tumor-promoting roles of ACh and CHRNA5, while rescue experiments confirmed that CHRNA5 knockdown abrogated ACh-induced effects. Notably, CHRNA5 inhibition produced more pronounced anti-tumor responses in C57BL/6 mice compared to BALB/c mice. Mechanistically, CHRNA5 shaped an immunosuppressive tumor microenvironment by transcriptionally upregulating CCL20 via CAMKII/AKT/NF-κB signaling, thereby promoting the recruitment of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs). Furthermore, the CAMKII inhibitor KN93 effectively suppressed both tumorigenesis and immune evasion.ConclusionCollectively, our findings identify CHRNA5 as a critical driver of PDAC progression by promoting malignant behaviors and reshaping the immune microenvironment, highlighting its potential as a promising therapeutic target in pancreatic cancer.
- Open Access
- 19 June 2025
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 19, 235-244
Synergistic effects of PAR2 and TrkA exacerbate visceral hypersensitivity induced by chronic pancreatitis in rats
- 19 June 2025
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 19, 235-244
Open AccessSynergistic effects of PAR2 and TrkA exacerbate visceral hypersensitivity induced by chronic pancreatitis in rats
Effect of perioperative high‐dose transdermal nicotine patch on pain sensitivity among male abstinent tobacco smokers undergoing abdominal surgery: A randomized controlled pilot study
Background and Aims: Previous studies have focused on the role of perioperative nicotine replacement therapy (NRT) in improving the success rate of long‐term smoking cessation in tobacco smokers. This study aimed to measure the effectiveness of high‐dose NRT in alleviating postoperative pain for male abstinent smokers receiving abdominal surgery.Design: This was a parallel‐group, randomized, double‐blind and controlled pilot trial.Setting and participants: In total, 101 male smoking‐abstinent patients from the Eastern Hepatobiliary Surgery Hospital, Shanghai, China, from 8 October 2018 to 10 December 2021.Interventions: Patients started smoking cessation on admission to the hospital ward. Patients received 24‐hour transdermal nicotine patches (n = 50) or placebo (n = 51) every day from admission until 48 hours after surgery.Measurements: The primary outcomes were pre‐surgery pain thresholds and total consumption of analgesics within the first 48 hours after surgery. Secondary outcomes included postoperative pain and sedation scores, nausea, vomiting and fever frequency within the treatment period.Findings: Both pre‐surgery electrical and mechanical pain thresholds in the NRT group were higher than those in the placebo group (P = 0.004 and P = 0.020, respectively). The 48‐hour postoperative analgesic consumption was significantly lower for smoking‐abstinent patients receiving NRT than those receiving placebo (standardized morphine equivalent requirement, median [interquartile range], 1.80 [1.47, 2.32] mg/kg vs 2.22 [1.62, 2.82] mg/kg, P = 0.011). Postoperative pain intensity was significantly lower in the NRT group than that in the placebo group at 1st hour and 24th hour post‐surgery (P < 0.001 and P = 0.012, respectively). The incidence of treatment‐related adverse events was not significantly different between groups.Conclusions: Perioperative high‐dose nicotine replacement therapy may help to relieve postoperative pain among male smoking‐abstinent patients undergoing abdominal surgery.
Effect of perioperative high‐dose transdermal nicotine patch on pain sensitivity among male abstinent tobacco smokers undergoing abdominal surgery: A randomized controlled pilot study
Background and Aims: Previous studies have focused on the role of perioperative nicotine replacement therapy (NRT) in improving the success rate of long‐term smoking cessation in tobacco smokers. This study aimed to measure the effectiveness of high‐dose NRT in alleviating postoperative pain for male abstinent smokers receiving abdominal surgery.Design: This was a parallel‐group, randomized, double‐blind and controlled pilot trial.Setting and participants: In total, 101 male smoking‐abstinent patients from the Eastern Hepatobiliary Surgery Hospital, Shanghai, China, from 8 October 2018 to 10 December 2021.Interventions: Patients started smoking cessation on admission to the hospital ward. Patients received 24‐hour transdermal nicotine patches (n = 50) or placebo (n = 51) every day from admission until 48 hours after surgery.Measurements: The primary outcomes were pre‐surgery pain thresholds and total consumption of analgesics within the first 48 hours after surgery. Secondary outcomes included postoperative pain and sedation scores, nausea, vomiting and fever frequency within the treatment period.Findings: Both pre‐surgery electrical and mechanical pain thresholds in the NRT group were higher than those in the placebo group (P = 0.004 and P = 0.020, respectively). The 48‐hour postoperative analgesic consumption was significantly lower for smoking‐abstinent patients receiving NRT than those receiving placebo (standardized morphine equivalent requirement, median [interquartile range], 1.80 [1.47, 2.32] mg/kg vs 2.22 [1.62, 2.82] mg/kg, P = 0.011). Postoperative pain intensity was significantly lower in the NRT group than that in the placebo group at 1st hour and 24th hour post‐surgery (P < 0.001 and P = 0.012, respectively). The incidence of treatment‐related adverse events was not significantly different between groups.Conclusions: Perioperative high‐dose nicotine replacement therapy may help to relieve postoperative pain among male smoking‐abstinent patients undergoing abdominal surgery.
- 1 December 2022
- Vol. 25 (9) , E1367-E1377
The Effect of Tramadol Versus Sufentanil on Controlling Postoperative Pain for Men Who Smoke and Do Not Smoke: A Randomized Clinical Trial
Background: Smoking behavior alters the analgesic threshold, which challenges postoperative pain management for patients who smoke.Objectives: We aimed to assess the analgesic efficacy of tramadol versus sufentanil in relieving postoperative pain for patients who do and do not smoke who underwent a partial hepatectomy.Study Design: Double-blinded randomized controlled trial.Setting: Eastern Hepatobiliary Surgery Hospital, Shanghai, China.Methods: All patients in this study were men. A total of 66 patients who smoke were randomly assigned to receive tramadol or sufentanil (n = 33 each). In addition, a total of 66 patients who do not smoke were randomly assigned to receive tramadol or sufentanil (n = 33 each). The primary outcome was the consumption of additional analgesics within the first 48 hours to control postoperative pain. Secondary outcomes included the postoperative pain level, the frequency of postoperative nausea and vomiting, the sedation score, and the frequency of fever within 48 hours postsurgery.Results: A significant interaction between "analgesic strategy " and "smoking history " was detected on the consumption of additional analgesics. In those who smoke, the requests for additional doses of analgesics were significantly less in those receiving tramadol than those receiving sufentanil; such a difference was not observed in those who do not smoke. The postoperative pain level was not significantly different between the tramadol group and the sufentanil group within patients who smoke within 48 hours postsurgery. The incidence of treatment-related adverse events was not significantly different between the tramadol group and the sufentanil group within both those who do and do not smoke.Limitations: Only men patients were included. Also, the superior analgesic effect and the incidence of adverse events of tramadol in patients who smoke were only assessed within the first 48 hours postsurgery.Conclusions: Our data suggest that tramadol has a better analgesic effect than sufentanil in relieving postoperative pain in patients who smoke.
- 1 December 2022
- Vol. 25 (9) , E1367-E1377
The Effect of Tramadol Versus Sufentanil on Controlling Postoperative Pain for Men Who Smoke and Do Not Smoke: A Randomized Clinical Trial
Background: Smoking behavior alters the analgesic threshold, which challenges postoperative pain management for patients who smoke.Objectives: We aimed to assess the analgesic efficacy of tramadol versus sufentanil in relieving postoperative pain for patients who do and do not smoke who underwent a partial hepatectomy.Study Design: Double-blinded randomized controlled trial.Setting: Eastern Hepatobiliary Surgery Hospital, Shanghai, China.Methods: All patients in this study were men. A total of 66 patients who smoke were randomly assigned to receive tramadol or sufentanil (n = 33 each). In addition, a total of 66 patients who do not smoke were randomly assigned to receive tramadol or sufentanil (n = 33 each). The primary outcome was the consumption of additional analgesics within the first 48 hours to control postoperative pain. Secondary outcomes included the postoperative pain level, the frequency of postoperative nausea and vomiting, the sedation score, and the frequency of fever within 48 hours postsurgery.Results: A significant interaction between "analgesic strategy " and "smoking history " was detected on the consumption of additional analgesics. In those who smoke, the requests for additional doses of analgesics were significantly less in those receiving tramadol than those receiving sufentanil; such a difference was not observed in those who do not smoke. The postoperative pain level was not significantly different between the tramadol group and the sufentanil group within patients who smoke within 48 hours postsurgery. The incidence of treatment-related adverse events was not significantly different between the tramadol group and the sufentanil group within both those who do and do not smoke.Limitations: Only men patients were included. Also, the superior analgesic effect and the incidence of adverse events of tramadol in patients who smoke were only assessed within the first 48 hours postsurgery.Conclusions: Our data suggest that tramadol has a better analgesic effect than sufentanil in relieving postoperative pain in patients who smoke.
- Open Access
- 20 July 2021
- Published by Springer Nature in Molecular Psychiatry
- Vol. 26 (12) , 7475-7480
Post-traumatic stress symptoms in COVID-19 survivors: a self-report and brain imaging follow-up study
Previous coronavirus pandemics were associated elevated post-traumatic stress symptoms (PTSS), but the self-report and neurological basis of PTSS in patients who survived coronavirus disease 2019 (COVID-19) are largely unknown. We conducted a two-session study to record PTSS in the COVID-19 survivors discharged from hospitals for a short (i.e., about 3 months, Session 1) to a medium period (i.e., about 6 months, Session 2), as well as brain imaging data in Session 2. The control groups were non-COVID-19 locals. Session 1 was completed for 126 COVID-19 survivors and 126 controls. Session 2 was completed for 47 COVID-19 survivors and 43 controls. The total score of post-traumatic stress disorder (PTSD) checklist for DSM-5 (PCL-5) score was significantly higher in COVID-19 survivors compared with controls in both sessions. The PCL-5 score in COVID-19 survivors was positively correlated with the duration after discharge (r = 0.27, p = 0.003 for Session 1), and increased by 20% from Session 1 to Session 2 for the survivors who participated both sessions. The increase was positively correlated with individual’s test-retest duration (r = 0.46, p = 0.03). Brain structural volume and functional activity in bilateral hippocampus and amygdala were significantly larger in COVID-19 survivors compared with controls. However, the volumes of the left hippocampus and amygdala were negatively correlated with the PCL-5 score for the COVID-19 survivors. Our study suggests that COVID-19 survivors might face possible PTSS deteriorations, and highlights the importance of monitoring mental wellness of COVID-19 survivors.
- 20 July 2021
- Published by Springer Nature in Molecular Psychiatry
- Vol. 26 (12) , 7475-7480
Open AccessPost-traumatic stress symptoms in COVID-19 survivors: a self-report and brain imaging follow-up study
Previous coronavirus pandemics were associated elevated post-traumatic stress symptoms (PTSS), but the self-report and neurological basis of PTSS in patients who survived coronavirus disease 2019 (COVID-19) are largely unknown. We conducted a two-session study to record PTSS in the COVID-19 survivors discharged from hospitals for a short (i.e., about 3 months, Session 1) to a medium period (i.e., about 6 months, Session 2), as well as brain imaging data in Session 2. The control groups were non-COVID-19 locals. Session 1 was completed for 126 COVID-19 survivors and 126 controls. Session 2 was completed for 47 COVID-19 survivors and 43 controls. The total score of post-traumatic stress disorder (PTSD) checklist for DSM-5 (PCL-5) score was significantly higher in COVID-19 survivors compared with controls in both sessions. The PCL-5 score in COVID-19 survivors was positively correlated with the duration after discharge (r = 0.27, p = 0.003 for Session 1), and increased by 20% from Session 1 to Session 2 for the survivors who participated both sessions. The increase was positively correlated with individual’s test-retest duration (r = 0.46, p = 0.03). Brain structural volume and functional activity in bilateral hippocampus and amygdala were significantly larger in COVID-19 survivors compared with controls. However, the volumes of the left hippocampus and amygdala were negatively correlated with the PCL-5 score for the COVID-19 survivors. Our study suggests that COVID-19 survivors might face possible PTSS deteriorations, and highlights the importance of monitoring mental wellness of COVID-19 survivors.
- 1 May 2021
- Published by Elsevier in Neuropharmacology
- Vol. 189, 108515
Nicotine withdrawal induces hyperalgesia via downregulation of descending serotonergic pathway in the nucleus raphe magnus
- 1 May 2021
- Published by Elsevier in Neuropharmacology
- Vol. 189, 108515
Nicotine withdrawal induces hyperalgesia via downregulation of descending serotonergic pathway in the nucleus raphe magnus